Cargando…
The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions
The consensus Immunoscore has a prognostic value that has been confirmed in two randomized phase 3 clinical trials, and it provides a reliable estimate of the recurrence risk in colon cancer. The latest edition of the WHO classification of the Digestive System Tumors introduced for the first time th...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480815/ https://www.ncbi.nlm.nih.gov/pubmed/32939329 http://dx.doi.org/10.1080/2162402X.2020.1812221 |